Multiple Locations Clinical Trials for Pleural Mesothelioma
1. University of California, University of Michigan, Wayne State University, Memorial Sloan Kettering Cancer Center, Barbara Ann Karmanos Cancer Institute
Name of Study:
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Study type:
Interventional
Purpose:
This is a phase 2 study and works in treating patients with malignant pleural mesothelioma that has come back. NAintedanib may stop growth of tumor cells by blocking some of the enzymes needed for cell growth. Patient will receive nentedanib by mouth on days 1-28. Course will be repeated every 28 days in the absence of disease progression or unacceptable toxicity.
ClinicalTrials.gov Identifier:
NCT02568449
Status:
Currently recruiting 55 patients, Oct. 2015 – Jan. 2017
Location:
University of California, University of Michigan, Wayne State University, Memorial Sloan Kettering Cancer Center
Contact:
University of California
David R. Gandara
916-734-8452
University of Michigan
Gregory P. Kalemkerian
734-615-4762
Wayne State University
Antoinette J. Wozniak
313-576-8752
Memorial Sloan Kettering Cancer Center
Marjorie G. Zauderer, M.D.
646-888-4201
2. 36 Locations, Morphotek Inc.
Name of Study:
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).
Study type:
Interventional
Purpose:
This is double blind randomized, parallel –group study using a placebo control or amatuximab 5 mg/kg administered weekly designed to evaluate the safety and efficacy of amatuximab in combination with pemetrexed and cisplatin
ClinicalTrials.gov Identifier:
NCT02357147
Status:
Currently recruiting November 2015-September 2020; 560 participants
Location:
36 locations
Contact:
Morphotek Inc.
info@morphotek.com
3. 83 Locations, Bayer Health
Name of Study:
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Study type:
Interventional
Purpose:
The purpose of the study is to study efficacy and safety of anetumab ravtansine vesus vinorelbine in progression free survival in patients with stage 1V mesothelioma
ClinicalTrials.gov Identifier:
NCT02610140
Status:
Active 210 participants
Location:
83 locations
Contact:
Bayer Health
clinical-trials-contact@bayerhealthcare.com
4. 145 Locations, Alliance for Clinical Trials in Oncology
Name of Study:
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Study type:
Interventional
Purpose:
Randomized phase 11 trial is studying how well pemetrexed disodium or observation works in treating mesothelioma patients without progressive disease after first line chemotherapy
ClinicalTrials.gov Identifier:
NCT01085630
Status:
Active April 2010- December 2020; 137 participants
Location:
145 locations
Contact:
Arkadiusz Dudek MD
312-413-8878
5. Bristol-Myers Squibb
Name of Study:
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)
Study type:
Interventional
Purpose:
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
ClinicalTrials.gov Identifier:
NCT02899299
Status:
Currently Recruiting October 2016,- September 2021 Estimated Enrollment 600
Location:
84 Study locations
Contact:
Bristol-Myers Squibb
Clincial.Trials@bms.com
6. Boehringer Ingelheim
Name of Study:
Nintedanib (BIBF 1120) in Mesothelioma
Study type:
Interventional
Purpose:
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.
ClinicalTrials.gov Identifier:
NCT01907100
Status:
Currently recruiting, September 2013-October 2019, Estimated enrollment 537
Location:
101 Study locations
Contact:
Boehringer Ingelheim Call Center
800-243-0127
7. Hoffmann-La Roche
Name of Study:
An Open-Label Study of Atezolizumab in Advanced Solid Tumors
Study type:
Interventional
Purpose:
The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the Investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.
ClinicalTrials.gov Identifier:
NCT02458638
Status:
Currently recruiting participants July 2015 – December 2020, Estimate enrollment 725
Location:
51 Study locations
Contact:
Reference Study ID Number: MO29518 2015-000269-30
888-662-6728
8. GlaxoSmithKline
Name of Study:
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
Study type:
Interventional
Purpose:
This phase IB trial aims to identify anticancer activity of GSK3052230 in subjects with malignancies with abnormal dependence on FGF pathway signaling. Combination doses of GSK3052230 with standard of care chemotherapy in the first and second line or greater setting of metastatic squamous non-small cell lung cancer (NSCLC) and first line malignant pleural mesothelioma subjects will be studied in the 3+3 dose-escalation design. This will be a multi-arm, multicenter, non-randomized, parallel-group, uncontrolled, open-label Phase IB study designed to evaluate the safety, tolerability and preliminary activity of GSK3052230 in combination with paclitaxel + carboplatin (Arm A), in combination with docetaxel (Arm B), or in combination with pemetrexed + cisplatin (Arm C). Approximately 70 subjects will be enrolled in the study (approximately up to 120 may be enrolled).
ClinicalTrials.gov Identifier:
NCT01868022
Status:
Active, not recruiting
Location:
37 Study locations
Contact:
US GSK Clinical Trials Call Center
877-379-3718
9. Roswell Park Buffalo New York & Abramson Cancer Center University of Pennsylvania
Name of Study:
MPM PDT Phase II Trial
Study type:
Interventional
Purpose:
A Randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post- operative chemotherapy improves the overall survival in the treatment of patients with epitheliod malignant pleural mesothelioma
ClinicalTrials.gov Identifier:
NCT02153229
Status:
Currently Recruiting May 2014 Completion date May 2018; Estimated enrollment 102
Location:
Roswell Park Buffalo New York & Abramson Cancer Center University of Pennsylvania
Contact:
Roswell
Michele Cooper, RN
716-845-4427
Abramson Cancer Center of The University of Pennsylvania
Sally Mcnulty, RN
215-662-7720
University of Pennsylvania
Keith Cengel, MD, PhD
855-216-0098
Mesothelioma Clinical Trial Information
Learn More About Mesothelioma
Did You Know?
Get Help from Experienced Mesothelioma Nurses
Learn more about these experienced mesothelioma nurses by watching the video below. Click here to contact a mesothelioma nurse now.
Learn More About MesoLawyersCare
Watch the video below to learn why MesoLawyersCare is the best choice to represent you and your family after a mesothelioma diagnosis.
Contact MesoLawyersCare Now
If you or a loved one has been diagnosed with mesothelioma, please contact us to see if we can help you get the compensation you deserve from the billions of dollars in asbestos trust funds available now for qualified asbestos victims. With just one call, you can put all our experience and success to work for you.
We have represented thousands of victims of mesothelioma and their families in virtually every State in the country and in decades of work have recovered billions of dollars in financial compensation for our clients.
Call us now at 1-888-568-1177, fill out the form on this page or chat with a live person. The consultation is free and it costs nothing upfront to hire the lawyers behind MesoLawyersCare. We only get paid if you collect a settlement or verdict and you will never receive a bill from us.
Receive a
FREE No Obligation
Legal Consultation Today
Important Notice: We are unable to help if:
- Diagnosis or passing was more than three years ago
- An attorney has already been retained in this matter
“You have all been so wonderful to us, so professional, and always looking out for our best interests in every way. I know it’s a job you do. However, not once did anyone ever make us feel like we did not matter.”